Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-03-25 Purchase | 2025-03-27 7:42 pm | Akero Therapeutics Inc. | AKRO | Graham G. Walmsley Director | 200,000 | $43.94 | $8,787,921 | 1,202,168 (Indirect Direct) | View |
| 2025-03-17 Sale | 2025-03-18 5:30 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,000 | $44.76 | $447,605 | 95,034 (Direct) | View |
| 2025-03-12 Sale | 2025-03-14 9:18 pm | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 1,738 | $44.88 | $78,001 | 654,324 (Direct) | View |
| 2025-03-12 Sale | 2025-03-14 8:33 pm | Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer | 607 | $44.88 | $27,242 | 260,540 (Indirect Direct) | View |
| 2025-03-12 Sale | 2025-03-14 8:30 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 614 | $44.88 | $27,556 | 95,034 (Direct) | View |
| 2025-03-12 Sale | 2025-03-14 8:24 pm | Akero Therapeutics Inc. | AKRO | White William Richard Chief Financial Officer | 676 | $44.88 | $30,339 | 61,959 (Direct) | View |
| 2025-03-12 Sale | 2025-03-14 8:18 pm | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 516 | $44.88 | $23,158 | 169,721 (Direct) | View |
| 2025-03-10 Sale | 2025-03-12 6:00 pm | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 30,000 | $41.77 | $1,253,069 | 656,062 (Direct) | View |
| 2025-03-05 Sale | 2025-03-07 5:30 pm | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 12,500 | $44.53 | $556,590 | 205,205 (Direct) | View |
| 2025-03-04 Sale | 2025-03-05 6:56 pm | Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer | 50,000 | $44.86 | $2,243,213 | 261,147 (Indirect Direct) | View |
| 2025-03-03 Sale | 2025-03-05 6:55 pm | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 1,000 | $48.09 | $48,090 | 111,674 (Direct) | View |
| 2025-02-18 Sale | 2025-02-21 5:31 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,000 | $49.87 | $498,660 | 105,648 (Direct) | View |
| 2025-02-10 Sale | 2025-02-11 9:30 pm | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 30,000 | $52.73 | $1,581,994 | 686,062 (Direct) | View |
| 2025-01-30 Purchase | 2025-02-07 7:54 pm | Akero Therapeutics Inc. | AKRO | Graham G. Walmsley Director | 200,000 | $48 | $9,600,000 | 1,002,168 (Indirect Direct) | View |
| 2025-02-05 Sale | 2025-02-07 6:05 pm | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 18,750 | $56.51 | $1,059,630 | 217,705 (Direct) | View |
| 2025-02-03 Sale | 2025-02-05 09:03 am | Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer | 10,000 | $53.81 | $538,061 | 311,147 (Indirect Direct) | View |
| 2025-01-27 Sale | 2025-01-31 09:14 am | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 53,590 | $56.25 | $3,014,216 | 148,433 (Direct) | View |
| 2025-01-27 Sale | 2025-01-31 09:14 am | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 49,074 | $55.72 | $2,734,212 | 149,069 (Direct) | View |
| 2025-01-27 Sale | 2025-01-29 8:43 pm | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 31,250 | $55.77 | $1,742,958 | 356,424 (Direct) | View |
| 2025-01-27 Sale | 2025-01-29 8:43 pm | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 5,000 | $57.03 | $285,150 | 112,674 (Direct) | View |
| 2025-01-27 Sale | 2025-01-29 8:43 pm | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 30,000 | $54.9 | $1,646,978 | 716,062 (Direct) | View |
| 2025-01-02 Sale | 2025-01-06 2:08 pm | Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer | 10,000 | $28.03 | $280,330 | 278,083 (Indirect Direct) | View |
| 2024-12-16 Sale | 2024-12-18 9:03 pm | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 1,000 | $29.13 | $29,130 | 86,358 (Direct) | View |
| 2024-12-16 Sale | 2024-12-18 9:01 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 9,074 | $29.11 | $264,117 | 189,348 (Direct) | View |
| 2024-12-17 Sale | 2024-12-18 8:52 pm | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 3,800 | $31.1 | $118,172 | 393,292 (Direct) | View |
| 2024-12-10 Sale | 2024-12-12 8:44 pm | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 4,818 | $30.91 | $148,934 | 317,092 (Direct) | View |
| 2024-12-10 Sale | 2024-12-12 8:38 pm | Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer | 2,503 | $30.79 | $77,067 | 263,783 (Indirect Direct) | View |
| 2024-12-10 Sale | 2024-12-12 8:29 pm | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 925 | $30.79 | $28,481 | 17,858 (Direct) | View |
| 2024-12-10 Sale | 2024-12-12 8:28 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 2,810 | $30.79 | $86,520 | 71,348 (Direct) | View |
| 2024-12-10 Sale | 2024-12-12 8:26 pm | Akero Therapeutics Inc. | AKRO | White William Richard Chief Financial Officer | 2,817 | $30.79 | $86,735 | 38,335 (Direct) | View |
| 2024-12-10 Sale | 2024-12-12 8:24 pm | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 7,855 | $30.79 | $241,855 | 597,562 (Direct) | View |
| 2024-12-02 Sale | 2024-12-04 7:36 pm | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 25,000 | $32.09 | $802,250 | 716,446 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-03-17 Exercise | 2025-03-18 5:30 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,000 | $21.1 | 95,034 (Direct) | View |
| 2025-03-17 Exercise | 2025-03-18 5:30 pm | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,000 | $0 | 95,034 (Direct) | View |
| 2025-03-05 Exercise | 2025-03-07 5:30 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 12,500 | $21.1 | 205,205 (Direct) | View |
| 2025-03-05 Exercise | 2025-03-07 5:30 pm | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 12,500 | $0 | 205,205 (Direct) | View |
| 2025-03-03 Exercise | 2025-03-05 6:55 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 1,000 | $19.87 | 111,674 (Direct) | View |
| 2025-03-03 Exercise | 2025-03-05 6:55 pm | N/A 2033-12-07 | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 1,000 | $0 | 111,674 (Direct) | View |
| 2025-02-18 Exercise | 2025-02-21 5:31 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,000 | $21.1 | 105,648 (Direct) | View |
| 2025-02-18 Exercise | 2025-02-21 5:31 pm | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,000 | $0 | 105,648 (Direct) | View |
| 2025-02-05 Exercise | 2025-02-07 6:05 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 18,750 | $21.1 | 217,705 (Direct) | View |
| 2025-02-05 Exercise | 2025-02-07 6:05 pm | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 18,750 | $0 | 217,705 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-31 09:14 am | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 15,172 | $6.364 | 148,433 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-31 09:14 am | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 16,849 | $0.615 | 148,433 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-31 09:14 am | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 21,569 | $21.09 | 148,433 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-31 09:14 am | N/A 2028-10-17 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 53,590 | $0 | 148,433 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-31 09:14 am | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 49,074 | $21.1 | 149,069 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-31 09:14 am | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 49,074 | $0 | 149,069 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-29 8:43 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 16,264 | $21.1 | 356,424 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-29 8:43 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 14,986 | $19.87 | 356,424 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-29 8:43 pm | N/A 2033-12-08 | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 31,250 | $0 | 356,424 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-29 8:43 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 4,000 | $19.87 | 112,674 (Direct) | View |
| 2024-12-31 Option Award | 2025-01-29 8:43 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 234 | $19.69 | 112,674 (Direct) | View |
| 2025-01-27 Exercise | 2025-01-29 8:43 pm | N/A 2033-12-07 | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 4,000 | $0 | 112,674 (Direct) | View |
| 2025-01-24 Exercise | 2025-01-27 6:08 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer | 43,064 | $6.364 | 321,147 (Direct) | View |
| 2025-01-23 Exercise | 2025-01-27 6:08 pm | N/A 2029-01-15 | Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer | 43,064 | $0 | 321,147 (Direct) | View |
| 2025-01-23 Exercise | 2025-01-27 6:07 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 50,000 | $0.615 | 798,274 (Direct) | View |
| 2025-01-23 Exercise | 2025-01-27 6:07 pm | N/A 2028-09-07 | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 50,000 | $0 | 798,274 (Direct) | View |
| 2025-01-07 Gift | 2025-01-10 7:38 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 14,000 | $0 | 170,237 (Direct) | View |
| 2024-12-26 Gift | 2024-12-30 8:20 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 14,100 | $0 | 184,237 (Direct) | View |
| 2024-12-16 Option Award | 2024-12-18 9:08 pm | N/A 2034-12-15 | Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer | 98,000 | $0 | 361,783 (Direct) | View |
| 2024-12-16 Option Award | 2024-12-18 9:03 pm | N/A 2034-12-15 | Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy | 69,500 | $0 | 86,358 (Direct) | View |
| 2024-12-16 Exercise | 2024-12-18 9:01 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 9,074 | $21.1 | 189,348 (Direct) | View |
| 2024-12-16 Exercise | 2024-12-18 9:01 pm | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 9,074 | $0 | 189,348 (Direct) | View |
| 2024-12-16 Option Award | 2024-12-18 9:01 pm | N/A 2034-12-15 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 98,000 | $0 | 189,348 (Direct) | View |
| 2024-12-16 Option Award | 2024-12-18 8:59 pm | N/A 2034-12-15 | Akero Therapeutics Inc. | AKRO | White William Richard Chief Financial Officer | 98,000 | $0 | 136,335 (Direct) | View |
| 2024-12-16 Option Award | 2024-12-18 8:56 pm | N/A 2034-12-15 | Akero Therapeutics Inc. | AKRO | Gangloff Scott A. Chief Technology Officer | 98,000 | $0 | 98,000 (Direct) | View |
| 2024-12-17 Exercise | 2024-12-18 8:52 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 3,800 | $19.87 | 393,292 (Direct) | View |
| 2024-12-17 Exercise | 2024-12-18 8:52 pm | N/A 2033-12-08 | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 3,800 | $0 | 393,292 (Direct) | View |
| 2024-12-16 Option Award | 2024-12-18 8:52 pm | N/A 2034-12-15 | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 80,000 | $0 | 393,292 (Direct) | View |
| 2024-12-16 Option Award | 2024-12-18 8:50 pm | N/A 2034-12-15 | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 394,100 | $0 | 991,662 (Direct) | View |
| 2024-12-10 Exercise | 2024-12-12 8:44 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 2,450 | $19.87 | 317,092 (Direct) | View |
| 2024-12-10 Exercise | 2024-12-12 8:44 pm | N/A 2033-12-08 | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 2,450 | $0 | 317,092 (Direct) | View |
| 2024-12-02 Exercise | 2024-12-04 7:36 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 25,000 | $21.1 | 716,446 (Direct) | View |
| 2024-12-02 Exercise | 2024-12-04 7:36 pm | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO | 25,000 | $0 | 716,446 (Direct) | View |